Pharming Group N.V. (AMS: PHARM)
Market Cap | 462.30M |
Revenue (ttm) | 259.04M |
Net Income (ttm) | -12.44M |
Shares Out | 678.35M |
EPS (ttm) | -0.02 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,054,301 |
Open | 0.672 |
Previous Close | 0.682 |
Day's Range | 0.668 - 0.684 |
52-Week Range | 0.648 - 1.313 |
Beta | 0.84 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Oct 24, 2024 |
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-1... [Read more]
Financial Performance
In 2023, BRNL's revenue was 1.33 billion, an increase of 12.58% compared to the previous year's 1.18 billion. Earnings were 31.65 million, an increase of 7.70%.
Financial numbers in USD Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/c/o/conf13-2624101.jpg)
Pharming Group to participate in September investor conferences
Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor co...
![](https://cdn.snapi.dev/images/v1/p/r/press14-2560213.jpg)
Pharming Group reports second quarter and first half 2024 financial results and provides business update
Leiden, the Netherlands, August 1, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second...
![](https://cdn.snapi.dev/images/v1/c/o/conf14-2531078.jpg)
Pharming Group to report second quarter and first half 2024 financial results on August 1
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024...
![](https://cdn.snapi.dev/images/v1/c/o/conf9-2458853.jpg)
Pharming Group to participate in June investor conferences
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor confere...
![](https://cdn.snapi.dev/images/v1/p/r/press15-2455150.jpg)
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
L eiden , the Netherlands, May 30, 2024 : Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing Au...
![](https://cdn.snapi.dev/images/v1/p/r/press3-2442021.jpg)
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, a...
![](https://cdn.snapi.dev/images/v1/c/o/conf8-2439371.jpg)
Pharming Group to participate in May investor conference
Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor confere...
![](https://cdn.snapi.dev/images/v1/p/r/press20-2432058.jpg)
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE I...
![](https://cdn.snapi.dev/images/v1/p/r/press12-2418021.jpg)
Pharming Group reports first quarter 2024 financial results and provides business update
Leiden, the Netherlands, May 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the three m...
![](https://cdn.snapi.dev/images/v1/c/o/conf7-2388065.jpg)
Pharming Group to report first quarter 2024 financial results on May 8
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial resu...
![](https://cdn.snapi.dev/images/v1/p/r/press13-2388031.jpg)
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized
![](https://cdn.snapi.dev/images/v1/p/r/press18-2381129.jpg)
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
![](https://cdn.snapi.dev/images/v1/p/r/press16-2378446.jpg)
Pharming Group announces the placement of €100 million convertible bonds due 2029
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
![](https://cdn.snapi.dev/images/v1/p/r/press3-2377765.jpg)
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
![](https://cdn.snapi.dev/images/v1/p/r/press15-2360838.jpg)
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency
![](https://cdn.snapi.dev/images/v1/p/r/press17-2356260.jpg)
Pharming Group announces the 2024 Annual General Meeting of Shareholders
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company's 2024 Annual General Meeting of Shareho...
![](https://cdn.snapi.dev/images/v1/p/r/press17-2356259.jpg)
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended Decemb...
![](https://cdn.snapi.dev/images/v1/p/r/press19-2323767.jpg)
Pharming Group reports fourth quarter and full year 2023 financial results
Leiden, The Netherlands, March 14, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the thre...
![](https://cdn.snapi.dev/images/v1/c/o/conf1-2300393.jpg)
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2...
![](https://cdn.snapi.dev/images/v1/c/o/conf14-2266681.jpg)
Pharming Group to participate in February investor conferences
Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor con...
![](https://cdn.snapi.dev/images/v1/p/r/press15-2220101.jpg)
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden, The Netherlan...
![](https://cdn.snapi.dev/images/v1/p/r/press10-2194397.jpg)
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2 Q 2024 Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (...
![](https://cdn.snapi.dev/images/v1/p/r/press18-2152244.jpg)
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstandi...
![](https://cdn.snapi.dev/images/v1/p/r/press3-2143614.jpg)
Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Leiden, The Netherlands, November 7, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces 14 poster presentations by the Company or its collaborat...
![](https://cdn.snapi.dev/images/v1/c/o/conf9-2132489.jpg)
Pharming Group to participate in November investor conferences
Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor con...